What's in Procter and Gamble's pipeline?

Procter and Gamble has 27 drugs in our index: 14 marketed, 0 filed, 3 in Phase 3, 2 in Phase 2, 8 in Phase 1.

Which companies overlap with Procter and Gamble's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Sanofi, Merck Sharp & Dohme LLC, Chinese University of Hong Kong, Hadassah Medical Organization.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/procter-and-gamble.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Procter and Gamble — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Procter and Gamble pipeline: 14 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

14 marketed 0 filed 3 Phase 3 2 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Aralasin	SARALASIN	marketed	saralasin	Type-2 angiotensin II receptor, Type-1 angiotensin II receptor, Angiotensin II receptor (AT-1) type-1	Hematology	1982-01-01
Didronel	ETIDRONIC ACID	marketed	Bisphosphonate		Bone	1977-01-01
250 ppm F as MFP	250 ppm F as MFP	marketed
Marketed toothpaste	Marketed toothpaste	marketed
Sodium monofluorophosphate toothpaste	Sodium monofluorophosphate toothpaste	marketed	Fluoride toothpaste	Tooth enamel hydroxyapatite; bacterial enolase	Dental/Oral Health
2800 ppm F as MFP	2800 ppm F as MFP	marketed
Sodium Fluoride Dentifrice	Sodium Fluoride Dentifrice	marketed	Fluoride topical agent	Tooth enamel hydroxyapatite; bacterial enolase	Dental/Oral Health
Marketed Cavity Protection Toothpaste	Marketed Cavity Protection Toothpaste	marketed	Fluoride-based remineralizing agent	Tooth enamel hydroxyapatite; oral bacterial metabolism	Dental/Oral Health
Test Stannous Fluoride Dentifrice	Test Stannous Fluoride Dentifrice	marketed
Sodium fluoride paste	Sodium fluoride paste	marketed	Topical fluoride agent	Tooth enamel hydroxyapatite	Dental/Oral Health
Stannous Fluoride Dentifrice	Stannous Fluoride Dentifrice	marketed	Topical fluoride dentifrice	Tooth enamel (hydroxyapatite); bacterial cell membranes	Dental/Oral Health
Sodium monofluorophosphate dentifrice	Sodium monofluorophosphate dentifrice	marketed	Fluoride dentifrice	Tooth enamel hydroxyapatite; bacterial enolase	Dental/Oral Health

Therapeutic area mix

Dental/Oral Health · 6
Gastroenterology · 2
Bone · 1
Diabetes · 1
Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 4 shared drug classes
Sanofi · 3 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Chinese University of Hong Kong · 2 shared drug classes
Hadassah Medical Organization · 2 shared drug classes
National Taiwan University Hospital · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Amgen · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Procter and Gamble:

Cite this brief

Drug Landscape (2026). Procter and Gamble — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/procter-and-gamble. Accessed 2026-06-10.